OOIR: Observatory of International Research

Papers

(The median citation count of Leukemia & Lymphoma is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Incidence of major bleeding in patients with chronic lymphocytic leukemia receiving ibrutinib and therapeutic anticoagulation	77
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study	41
Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF)	39
Impact of SF3B1 mutation in myelofibrosis	35
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma	31
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant	30
CRLF2 and IKZF1 abnormalities in childhood hematological malignancies other than B-cell Acute Lymphoblastic Leukemia	30
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia	24
Embelin inhibits viability of cutaneous T cell lymphoma cell lines HuT78 and H9 by targeting inhibitors of apoptosis	23
CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study	23
The inherited genetic contribution and polygenic risk score for risk of CLL and MBL: a narrative review	23
CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state	22
Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma	22
Management of relapsed/refractory mantle cell lymphoma	21
Use of PD-1 blockade in refractory/relapsed natural killer T-cell lymphomas: a systematic review and synthesis of case reports	21
Improvement in mortality of hospitalized patients with hematological malignancies in the 2nd wave of COVID-19 in the UK: experience of a large London NHS trust	20
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents	20
Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study	20
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia	19
Indolent B-cell non-Hodgkin lymphomas in children: high association with inborn errors of immunity	19
Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management	19
New therapies for angioimmunoblastic T-cell lymphoma: a comprehensive review and analysis	19
High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination	19
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia	19
Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma	18

Correction	18
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim ¹⁸ F-FDG PET/CT scans	17
Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma	16
Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)	16
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes	16
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma	15
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis	15
Transplantation provides superior survival high risk myeloid malignancies in older patients	15
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clini	15
Organ toxicities associated with chimeric antigen receptor T-cell therapy	15
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia	15
MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma	15
Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax	14
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma	14
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma	14
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy	14
XX International workshop on chronic lymphocytic leukemia	13
Making the case for the case report – informing physicians of intracranial hypertension as an adverse event in tyrosine kinase inhibitor treated chronic myeloid leukemia patients	13
Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study	13
Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy	13
Analysis of albumin as a prognostic factor in HHV-8/HIV-negative Castleman disease from a multicenter study	13
Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?	13
COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome	13
Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience	13
Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic	13
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges	13
Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice	12
Cost-Effectiveness of brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma	12
Interferon maintenance for prevention of relapse in favorable risk AML?	12
Richter transformation – retrospective treatment outcomes analysis in Polish Adult Leukemia Study Group	12
PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1-like acute lymphoblastic leukaemia in Indian patients	12
Progressive eosinophilia and STAT5B mutation acquisition in AML treated with azacitidine and venetoclax	12
CML stem cells and their interactions and adaptations to tyrosine kinase inhibitors	12
Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplanta	12
Rare HNRNPH1::ERG rearrangement in a case of de novo pediatric AML and review of cases	12
Serum lipid trajectories in the years before a lymphoma diagnosis	12
Successful treatment with belantamab mafodotin in a heavily pretreated patient with multiple myeloma and liver extramedullary disease	12
A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma	11
NOTCH signaling in the pathogenesis of splenic marginal zone lymphoma—opportunities for therapy	11
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma	11
Trametinib enhances ATRA-induced differentiation in AML cells	11
Infections in secondary immunodeficiency patients treated with Privigen^®or Hizentra^®: a retrospective US administrative claims study in patients with hematological malignancies	11
Pretreatment serum level of interleukin-6 predicts carfilzomib-induced hypertension in relapsed/refractory multiple myeloma	11
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification	11
Evaluation of non-research and research industry payments to pediatric hematologist/oncologists in the United States between 2013 and 2021	11
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy	10
Association between plasma venetoclax trough levels and serum C-reactive protein levels in patients with acute myeloid leukemia treated with venetoclax plus azacitidine	10
A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse	10
Targeting mitochondrial metabolism in acute myeloid leukemia	10
[ ²¹¹ At]astatine-based anti-CD22 radioimmunotherapy for B-cell malignancies	10

Correction	10
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation	10
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS	10
Impact of chronic graft- versus -host disease on non-relapse mortality and survival	10
Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression	10
Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma	10
A single-center analysis of patients with extranodal marginal zone lymphoma of the breast	10
Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases	10
Chemotherapy-free approach with arsenic trioxide and all-trans retinoic acid in children with acute promyelocytic leukemia	10
Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir	10
Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression	10
Megakaryocyte centrosomal and Golgi structural perturbations in patients with primary myelofibrosis and with RUNX1 germline mutation	10
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia	9
Healthcare resource use and reimbursement amount by site of care in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell (CAR-T) therapy – a retrospective cohort stud	9
The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia	9
Sun protection behaviors among adult survivors receiving hematopoietic cell transplantation: a cross-sectional survey of a single institution in Japan	9
A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas	9
The diagnosis of Burkitt lymphoma: how do pathologists apply criteria in daily practice?	9
Low-risk relapsed acute lymphoblastic leukemia in children and young adults: what have we learnt and what’s next?	9
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia	9
Prediction for sustained deep molecular response for treatment-free remission	9
Prognostic impact of TP53 mutations in adult acute lymphoblastic leukemia treated with a pediatric-type regimen	9
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics	9
The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma	9
Two recurrent types of IGH ::5′ BCL2 breakpoints representing cytogenetic ins(14;18)(q32;q21q21) and t(14;18)(q32;q21), mediated by the	9
A phase 1 study of interleukin-15 in combination with avelumab in relapsed or refractory T-cell lymphoma	9
Effectiveness and safety of leukapheresis in hyperleukocytic leukemias: a retrospective multicenter study	9
Paraneoplastic cerebellar degeneration in a patient with multiple myeloma	9
The diagnostic profile of rare acute myelomegakaryoblastic leukemia	9
Achievement of durable remission of relapsed/refractory acute myeloid leukemia in a child using venetoclax monotherapy	9
Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma	9
Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study	9
The International Prognostic Score and HIV status predict red cell concentrate transfusion needs in Hodgkin lymphoma	9
Prospects for liquid biopsy approaches in lymphomas	9
Serological response following vaccination with BNT162b2 mRNA in patients with chronic lymphocytic leukemia	9
Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity	9
Lymphocyte HLA-DR/CD-38 co-expression correlates with Hodgkin lymphoma cell cytotoxicity in vitro independent of PD-1/PD1-L pathway	9
COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study	9
Lenalidomide, rituximab (R ² ), and ixazomib for frontline treatment of high risk follicular and indolent non-Hodgkin lymphoma	8
Improved overall survival over time in advanced stage mycosis fungoides: a cross-sectional study	8
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison	8
Blastic plasmacytoid dendritic cell neoplasm with history of myeloma and concomitant acute undifferentiated leukemia: Illustration of morphologic and immunophenotypic challenges of an emerging phenome	8
Fatigue – a substantial problem in hematology, but what can be done?	8
TP53 -altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs	8
Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients	8
Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients	8
Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transpl	8
White blood cell count nadir to zero following intensive chemotherapy as a predictive factor for patients with acute myeloid leukemia	8
Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas	8
Denosumab versus intravenous bisphosphonate use for hypercalcemia in multiple myeloma	8
Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding	8
Response to trametinib of two pediatric myeloid malignancies cases harboring RAS mutation and monosomy 7	8
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission	8
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial	8
Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice	8
Clinical characteristics and outcomes of Brazilian patients with duodenal-type follicular lymphoma: a multicenter retrospective study	8
Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab	8
Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach	8
Emerging drug profile: JAK inhibitors	8
A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström’s macroglobulinemia	8
MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis	8
Graft failure after “ex-vivo” T-cell depleted haploidentical transplantation in pediatric patients with high-risk hematological malignancies. A risk factors and outcomes analysis	8
Combined impact of HLA-allele matching and the CD34-positive cell dose on optimal unit selection for single-unit cord blood transplantation in adults	8
CALR -mutated myeloproliferative neoplasms	8
Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation	8
Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin	7
Labile CD22 and CD19 expression in a case of Philadelphia chromosome-like acute lymphoblastic leukemia	7
HHV8-Negative Effusion-Based lymphoma in a patient with recurrent HCV hepatitis status post liver transplantation	7
Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK + LBCL): a systematic review of clinicopathological features and management	7
Optimizing pegaspargase therapy in patients with hypersensitivity reactions	7
Clinical and molecular characterization of myeloid sarcoma without medullary leukemia	7
Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes	7
Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation	7
Therapeutic approach to patients with early stage diffuse large B cell lymphoma: retrospective, multicenter, real-life study of the ‘RTL’ (regional Tuscan lymphoma network)	7
Leukocytosis and MPNs: Where do we stand?	7
Evaluation of a safe neutrophil count for cessation of intravenous antibiotics and early hospital discharge in stable, afebrile patients recovering after acute myeloid leukemia therapy or an autograft	7
Promising activity of single agent nivolumab followed by low-dose whole brain radiotherapy in isolated central nervous system relapse of Hodgkin lymphoma	7
A de novo germline RUNX1 variant preceding development of concurrent T-lymphoblastic leukemia and myelodysplastic syndrome	7
Mitigating time toxicity in lymphoma and multiple myeloma	7
The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study	7

CCND2 mutations in atypical chronic myeloid leukemia: a report of two cases	7
Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin	7
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation	7
Retrospective multicenter comparative study of the efficacy and safety between R-DHAC and R-DHAOx in diffuse large B-cell lymphoma or transformed follicular or marginal zone B lymphoma into aggressive	7
COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies	7
Mean platelet volume may not be a predictive and prognostic marker in patients with acute myeloid leukemia	7
Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance	7
Allogeneic transplant graft source – conditioning – GVHD prophylaxis: don’t mix and match!	7
Prevalence and clinicopathological features of incidentally detected TRBC1-dim populations in peripheral blood flow cytometry	7
Ixazomib-induced thrombotic microangiopathy resolving without complement pathway inhibition: a case report	7
Anticipation in hematopoietic malignancies: biology, bias, or both?	7
Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy	7
Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma	7
Myeloid/lymphoid neoplasm with a novel cryptic RBPMS::FGFR1 rearrangement presenting as de novo acute leukemias	7
Normal and malignant cells are homogeneously distributed in the bone marrow of children	7
Genomic landscape of T-large granular lymphocyte leukemia and chronic lymphoproliferative disorder of NK cells: a single institution experience	7
Characterization of the calcineurin inhibitor pain syndrome in patients undergoing allogeneic hematopoietic cell transplantation	6
Consistency of the efficacy of immunotherapy with histamine dihydrochloride and low-dose interleukin-2 for relapse prevention in acute myeloid leukemia	6
Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma	6
Correction	6
A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma	6
Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma	6
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases	6
Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group	6
Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey	6
Indolent relapse after initial aggressive B-cell lymphoma: a single institution experience in the rituximab era	6
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma	6
Determinants of ten-year overall survival of acute myeloid leukemia: a large national cancer database analysis	6
Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma	6
Inter-racial genetic differences in myelofibrosis: a diverse inner-city center analysis	6
Preclinical and clinical evaluation of Buparlisib (BKM120) in recurrent/refractory Central Nervous System Lymphoma	6
Precision and strategic targeting of novel mutation-specific vulnerabilities in acute myeloid leukemia: the semi-centennial of 7 + 3	6
Improving outcomes in limited-stage de novo CD5+ DLBCL: systemic approaches with consolidative radiation	6
A case of testicular diffuse large B-cell lymphoma with late relapse in the skin: the critical role of comparative phenotypic, clonality, and cytogenetic testing	6
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort	6
Correction	6
A novel ETV6::FGFR1 fusion gene in a myeloid/lymphoid neoplasm with FGFR1 rearrangement sensitive to specific FGFR1-2-3	6
Patterns of care and outcomes of early stage I–II Hodgkin lymphoma treated with or without radiation therapy	6
Tagraxofusp as first-line treatment for blastic plasmacytoid dendritic cell neoplasm	6
Impact of the addition of rituximab in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia	6
Ixazomib in addition to chemotherapy for the treatment of acute myeloid leukemia in older adults	6
Follicular lymphoma of the lower female genital tract: an indolent and localized extranodal follicular lymphoma with mutation of TNFRSF14	6
Acalabrutinib is an effective treatment for immune thrombocytopenia associated with chronic lymphocytic leukemia, a case report	6
CD5- B-cell lymphocytic leukemia –a diagnostic exclusion of splenic B-cell leukemia with prominent nuclei challenging current international consensus	6
Central nervous system (CNS) involvement has an adverse impact on survival in newly diagnosed adult acute lymphoblastic leukemia (ALL) assessed by flow cytometry	6
Lower intensity regimens for acute myeloid leukemia: opportunities and challenges	6
Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma	6
Moving beyond traditional clinical trial endpoints: patient-reported outcomes illuminate the patient experience of novel AML therapies	6
Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone	6
Polymerase chain reaction in the diagnosis of invasive aspergillosis: approaches for appropriate use	6
Performance of the frailty index in predicting complete remission, intensive care unit admission, and overall mortality in older and younger patients with acute myeloid leukemia receiving intensive ch	6
A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia	6
Reduced prognostic value of beta-2-microglobulin for time to first treatment in CLL patients with compromised kidney function	6
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin ( NPM1 ) gene mutation subtypes: a single-center experience and re	6
EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16	6
Successful treatment of acquired von Willebrand syndrome secondary to low-grade CLL with rituximab and venetoclax	6
Treatment of relapsed and refractory Waldenstrom Macroglobulinemia	5
Identification and genetic characterization of a NUP98-HHEX molecular rearrangement in a pediatric acute myeloid leukemia	5
Integrated genomic and single-cell transcriptomic analyses reveal clonal evolution and immune signature in donor cell leukemia after haploidentical allogeneic hematopoietic stem cell transplantation	5
Phase 1/2 multicenter trial of acalabrutinib in Chinese patients with relapsed/refractory mantle cell lymphoma	5
Distinct immune-response profile of Richter transformation chronic lymphocytic leukemia (CLL), defined by high expression of PD1, LAG3, TIM3 and IL-10	5
Innovative management of BK virus nephropathy post-HSCT: a case report and therapeutic insights	5
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant	5
Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies	5
Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis	5
The prognostic role of NKG2A expression for patients with chronic myeloid leukemia after treatment discontinuation	5
Flow cytometry is a sensitive technique to assess marrow involvement by B cell non-Hodgkins lymphoma	5
Prognostic assessment value of immune escape-related genes in patients with acute myeloid leukemia	5
What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?	5
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study	5
Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study	5
Therapeutic approaches for the management of higher risk myelodysplastic syndromes	5
RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia	5
An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study	5
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor	5
TP53/PLCG2-mutated diffuse large B-cell lymphoma richter transformation (DLBCL-RT) of CLL with unusual CD2 and PD-1 expression	5
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group	5
Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination	5
RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL	5
The pretreatment Controlling Nutritional Status score is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma	5
Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia	5
A novel murine syngeneic CD8 peripheral T-cell lymphoma model with preclinical applications	5
The clinical characteristics and prognosis of patients with primary plasma cell leukemia (pPCL) according to the new IMWG definition criteria	5
The promising outcome with simultaneous integrated boost intensity modulated radiotherapy in confined nasal extranodal NK/T-cell lymphoma	5
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute	5
Fish evaluation of additional cytogenetic aberrations and hyperdiploidy in childhood Burkitt lymphoma	5
Glycated hemoglobin (HbA1c) and thrombotic risk in polycythemia vera and essential thrombocythemia	5
Comprehensive analysis of the genetic landscape of 21 cases with blastic plasmacytoid dendritic cell neoplasm by whole genome and whole transcriptome sequencing	5
A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomono	5
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study	5
Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma	5
Correction	5
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation	5
Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma	5
Calcific tendinopathy: an unexpected side effect of tyrosine kinase inhibitor?	5